Breaking Down Medicover AB (publ) Financial Health: Key Insights for Investors

If you're tracking healthcare plays in Europe, Medicover AB's recent results demand a close look: Q4 2024 revenue jumped to €555.8 million (up 20.3% y/y) and full-year 2024 revenue reached €2,091.8 million (up 19.8% y/y), while TTM revenue as of 30 Sep 2025 hit €2.32 billion (+16.23% y/y), but beneath top-line momentum lies a mixed profitability and balance-sheet picture-full-year EBITDA was €284.9 million (margin 13.6%), Q4 EPS slipped to €0.058, and net profit margin narrowed to 1.3%; leverage and liquidity metrics raise flags with total debt of €13.2 billion, a debt-to-equity ratio of 2.74, current ratio 0.78 and an Altman Z-Score of 2.2-yet forward-looking valuation and growth projections show investors expect more (forward P/E 33.38, EV/EBITDA 13.49) and analysts forecast EPS growth of 27.4% p.a. alongside revenue growth of 10.6% p.a., boosted by recent acquisitions adding ~€80 million of annualized revenue and a board-proposed 25% dividend increase for 2024; read on for a detailed breakdown of Revenue, Profitability, Debt, Liquidity, Valuation and the key risks and opportunities that will determine whether Medicover's premium valuation is justified.

Medicover AB (0RPS.L) - Revenue Analysis

Medicover AB's top-line trajectory through 2024-2025 shows strong expansion driven by both organic growth and acquisitions. Key quarterly, annual and trailing figures illustrate sustained momentum across healthcare and diagnostic services.

• Q4 2024 revenue: €555.8 million (up 20.3% vs Q4 2023 €461.9m); organic growth 18.6%.
• Full year 2024 revenue: €2,091.8 million (up 19.8% vs 2023 €1,746.4m); organic growth 16.7%.
• Q1 2025 revenue per share: SEK 3.85 (from SEK 3.70 in Q4 2024), indicating sequential growth.
• Q3 2025 revenue: €591.6 million, a 12.09% increase from Q2 2025.
• TTM revenue as of 30 Sep 2025: €2.32 billion (up 16.23% YoY).

Drivers and implications for investors:

• Organic growth (16.7-18.6% range in 2024) signals strong underlying demand in core markets.
• Sequential revenue-per-share increase from SEK 3.70 to SEK 3.85 suggests improving revenue productivity per equity unit in early 2025.
• TTM of €2.32bn reflects scale expansion and provides a current rolling baseline for valuation multiples and margin analysis.
• Quarterly acceleration to €591.6m in Q3 2025 supports upward revenue trend but warrants monitoring for seasonality and one-off items.

For more on the company's background and business model, see: Medicover AB (publ): History, Ownership, Mission, How It Works & Makes Money

Medicover AB (0RPS.L) - Profitability Metrics

Medicover AB (0RPS.L) reported clear improvement in core profitability metrics in 2024, driven by higher EBITDA and margin expansion, while bottom-line metrics showed pressure from non-operational items and tax/finance effects.

• Q4 2024 EBITDA: €73.2 million (+10.2% vs Q4 2023 €66.4m)
• Q4 2024 EBITDA margin: 13.2%
• Adjusted EBITDA margin (Q4 2024): improved by 80 basis points year-over-year
• Full-year 2024 EBITDA: €284.9 million (+16.9% vs 2023 €243.8m)
• Full-year 2024 EBITDA margin: 13.6%
• Q4 2024 EBIT (operating profit): €23.3 million (operating margin 4.2%)
• Q4 2024 net profit margin: 1.3% (down from 1.9% in Q4 2023)
• Q4 2024 EPS: €0.058 (Q4 2023: €0.078)

Key drivers behind the numbers include revenue growth and operational efficiencies lifting EBITDA and adjusted margins, while lower net margin and EPS reflect higher non-operating costs or tax impacts in the quarter. For related investor context, see: Exploring Medicover AB (publ) Investor Profile: Who's Buying and Why?

Medicover AB (0RPS.L) - Debt vs. Equity Structure

• Total debt: €13.2 billion (30 June 2025)
• Cash and equivalents: €996.1 million (30 June 2025)
• Debt-to-equity ratio: 2.74
• Leverage ratio (net debt / EBITDA proxy): 3.0x (improved from 3.4x year-over-year)
• Q1 2025 CapEx: €28 million (5.8% of revenue)
• Net operating cash flow (Q4 2024): €64.2 million (vs. €42.5 million in Q4 2023)
• Free cash flow (Q4 2024): €44.2 million (vs. €14.8 million in Q4 2023)

• Improving leverage (3.0x vs 3.4x) signals progress in debt management and/or EBITDA growth.
• Significant free cash flow improvement in Q4 2024 provides buffer for interest and principal amortization.
• CapEx at 5.8% of revenue suggests moderate reinvestment-enough to support growth without excessive capital strain.
• Cash holdings (~€1.0bn) reduce short-term liquidity risk but remain small relative to the €13.2bn gross debt stock.

Medicover AB (0RPS.L) - Liquidity and Solvency

• Current ratio: 0.78 (below the industry benchmark of 1.0) - potential liquidity constraints to cover current liabilities with current assets.
• Quick ratio: 0.68 - limited ability to meet short-term obligations using liquid assets (excludes inventories).
• Interest coverage ratio: 2.58 - moderate cushion to service interest expense, but not ample.
• Altman Z-Score: 2.2 - indicates increased bankruptcy risk relative to healthier firms (Z > 2.99 generally considered safe).
• Piotroski F-Score: 7 - strong operational and accounting fundamentals, suggesting quality earnings and improvements in profitability and balance-sheet metrics.
• Net cash flow from operating activities (Q4 2024): €64.2 million, up from €42.5 million in Q4 2023 - meaningful improvement in cash generation.

• Implications for short-term liquidity: working capital management and timing of payables/receivables will be critical given a sub-1 current ratio and low quick ratio.
• Debt-servicing risk: an interest coverage of 2.58 provides only a moderate buffer; rising rates or margin pressure could tighten coverage quickly.
• Offsetting strengths: a Piotroski F-Score of 7 and strong operating-cash improvement (Q4 2024) support operational resilience despite balance-sheet tightness.
• Credit/solvency watch: Altman Z-Score of 2.2 places Medicover in a cautionary zone - worth monitoring capital structure actions and any material changes in profitability or cash flow.

Medicover AB (0RPS.L) - Valuation Analysis

• Trailing P/E: 49.35 - indicates a high price relative to last 12 months' earnings, signaling investor willingness to pay for current earnings.
• Forward P/E: 33.38 - suggests anticipated earnings growth that narrows the premium versus trailing earnings.
• P/S (Price-to-Sales): 1.43 - implies the market values each krona of revenue at a modest multiple, supporting revenue-backed valuation.
• P/B (Price-to-Book): 6.37 - reflects a significantly higher market valuation versus book equity, typical for service-oriented healthcare firms with intangible assets.
• EV/EBITDA: 13.49 - a moderate enterprise-value multiple versus operating cash-profit, consistent with growth-sector peers.
• EV/FCF: 28.34 - denotes a relatively rich valuation when measured against free cash flow, indicating expectations for future cash conversion or continued margin expansion.

Medicover AB (0RPS.L) - Risk Factors

Medicover AB (0RPS.L) exhibits a mixed financial profile: operational strengths offset by notable leverage and liquidity pressures. Investors should weigh the quantified risks below against the company's operational performance and market exposure.

• Debt-to-Equity Ratio: 2.74 - high financial leverage increases vulnerability to interest-rate rises and revenue shocks.
• Current Ratio: 0.78 - indicates potential short-term liquidity stress and reliance on rolling financing or working capital management.
• Altman Z-Score: 2.2 - signals elevated bankruptcy risk relative to healthy benchmarks (typically Z > 3 for low risk).
• Piotroski F-Score: 7 - strong operational and accounting fundamentals that mitigate some risks (score range 0-9; 7 indicates generally sound financial health).
• Dividend Policy: Proposed 25% increase in dividends for 2024 - reflects board confidence but could strain cash resources if free cash flow weakens.
• Geographic Exposure: Significant operations in India and Germany - creates growth and regulatory divergence risks due to differing healthcare markets, reimbursement systems, and policy regimes.

Risk vectors to monitor closely:

• Refinancing risk - high leverage (D/E 2.74) increases sensitivity to credit market tightening and interest-rate rises.
• Liquidity risk - current ratio below 1.0 (0.78) suggests a need for robust working capital management or access to committed credit facilities.
• Financial distress signal - Altman Z-Score of 2.2 places the company in a zone where downturns can quickly erode solvency.
• Dividend sustainability - a 25% dividend increase in 2024 could reduce financial flexibility if cash flow generation underperforms projections.
• Geopolitical and regulatory risk - operations in India and Germany expose Medicover to differing reimbursement rules, labor markets, and regulatory enforcement intensity.
• Operational mitigation - a Piotroski F-Score of 7 indicates strong internal signals (profitability, cash flow, and balance sheet improvements) that partially offset external risks.

For context on investor behavior and ownership trends related to Medicover AB (0RPS.L), see: Exploring Medicover AB (publ) Investor Profile: Who's Buying and Why?

Medicover AB (0RPS.L) - Growth Opportunities

Medicover AB (0RPS.L) is positioned for accelerated growth driven by high single- to double-digit topline expansion, margin recovery in diagnostics and targeted M&A that immediately boosts scale. Key publicly noted forecasts and corporate actions underline a multi-year expansion thesis for investors.

• Analyst/consensus growth outlook: earnings +29.5% p.a., revenue +10.6% p.a., EPS +27.4% p.a.
• Company performance: management has already met or exceeded its 2025 year‑end financial targets with three quarters to spare.
• Dividends: the board proposed a 25% increase in the 2024 dividend, signaling confidence in cash flow and capital allocation.

Recent strategic M&A and organic momentum create a compound growth runway:

• Acquisitions - SYNLAB assets and a Polish fitness operator - expected to add approximately €80 million of annualized revenue.
• Diagnostics division - reported robust organic growth and margin improvement, notably despite pricing pressures from Germany's public sector tenders.
• German private-pay market - expanding rapidly and representing a scalable, higher-margin channel for Medicover's diagnostics and healthcare services.

For background on the company's history, ownership and business model see: Medicover AB (publ): History, Ownership, Mission, How It Works & Makes Money